Factors Affecting Survival on Biologic Treatments in Patients with Rheumatoid Arthritis: A Single-Center Study From Turkey
Abstract
Objective: In our study, we aimed to determine the factors affecting survival on biologic treatment in adult rheumatoid arthritis (RA) patients using biolog-
ical drugs.
Materials and Methods: In our study, the data of 245 patients who were followed up with the diagnosis of RA in the Rheumatology Clinic of Trakya
University Medical Faculty Hospital between 2013 and 2016 were analyzed retrospectively. 37 patients were excluded due to missing data. The data of the
remaining 208 patients were evaluated.
Results: In our study, we found that drug survival was reduced by 0.48 times (95% CI 0.23-0.97) in elderly patients and 3 times (95% CI 1.09-10.3) in
females. According to the results of our study, drug survival is shortened 8 times (95% CI 2.12-32.5) in patients with hyperlipidemia and 1.03 times (95%
CI 1.01-1.04) in patients with high pretreatment erythrocyte sedimentation rate (ESR). In addition, we found that shorter drug survival 9.2 times (95% CI
2.4-35.3) in patients with Hepatitis B surface antigen (HBsAg) positivity, 2.9 times (95% CI 1.3-6.4) in patients with antibody positivity against citrullinated
protein (ACPA), in patients using glucocorticoids 0.36 times (95% CI 0.17-0.76). Despite that; in patients with chronic kidney disease, drug survival was
prolonged by 0.18 times (95% CI 0.06-0.57).
Conclusion: When starting biologic drugs in RA patients, some parameters may help to predict drug survival. According to the order of effect; while HBsAg
positivity, presence of hyperlipidemia, female gender, ACPA positivity, high ESR, advanced age and glucocorticoid use were negative markers for drug
survival; chronic kidney damage can be a positive marker.
Keywords
Biological agents , Rheumatoid arthritis , Tumor necrosis factor
Kaynakça
- McInnes I. B, Schett G. Pathogenetic insights from thetreatment of rheumatoid arthritis. Lancet 2017;389:2328–2337.
- Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094–1108
- Lipsky PE. Romatoid artrit (çeviri: S. Akar). Akkoç N, Biberoğlu K. (Editörler). Harrison’s Principles of Internal Medicine Cilt 2. İstanbul: Nobel Tıp Kitabevleri; 2013.
- Smolen J. S, Aletaha D, Koeller M, Weisman M. H, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861–1874.
- Smolen J.S, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados et. al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. BMJ. 2017;76:960–977.
- Alptekin D. Ö. Romatizmal hastalıkların kullanılan biyolojik ajanlara güncel bakış. Bidder Tıp Bilimleri Dergisi, 2011;3(3):41-49.
- Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol. 2011;38(8):1552-1562.
- Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther.2010;10(9):1367-11378.
- Leon L, Rodriguez LR, Rosales Z, Gomez A, Lamas JR, Pato E et. al. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol. 2016;45(6):456-460.
- Gulácsi L, Rencz F, Poór G, Szekanecz Z, Brodszky V, Baji P et.al. Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann Rheum Dis. 2016;75(5):942-943.